Peter A. Lewitt
#153,057
Most Influential Person Now
Peter A. Lewitt's AcademicInfluence.com Rankings
Peter A. Lewittphilosophy Degrees
Philosophy
#8540
World Rank
#11947
Historical Rank
Logic
#5569
World Rank
#6977
Historical Rank
Peter A. Lewittbiology Degrees
Biology
#11580
World Rank
#14984
Historical Rank
Neuroscience
#1886
World Rank
#1942
Historical Rank
Download Badge
Philosophy Biology
Why Is Peter A. Lewitt Influential?
(Suggest an Edit or Addition)Peter A. Lewitt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial (2011) (564)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- Levodopa in the treatment of Parkinson's disease: Current controversies (2004) (370)
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa (1996) (356)
- Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions (1995) (344)
- Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) (2008) (333)
- A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains (1995) (328)
- Urate as a predictor of the rate of clinical decline in Parkinson disease. (2009) (324)
- Advanced Parkinson disease treated with rotigotine transdermal system (2007) (258)
- Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
- Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders (1996) (230)
- A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. (2001) (216)
- The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1985) (215)
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics (2015) (208)
- Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment (2005) (207)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Cognitive impairments in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes (1984) (198)
- Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement (2014) (166)
- Levodopa for the treatment of Parkinson's disease. (2008) (158)
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial (2006) (151)
- Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases (2003) (142)
- Insulinopenic Diabetes After Rodenticide (Vacor) Ingestion: A Unique Model of Acquired Diabetes in Man (1980) (139)
- Reliability of a new scale for essential tremor (2012) (136)
- Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease: Long-term Exposure (2008) (133)
- Blink rates and disorders of movement (1984) (130)
- Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease. (2014) (127)
- Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. (2015) (124)
- 3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis (2013) (120)
- Glutamate and other CSF amino acids in Alzheimer's disease. (1992) (115)
- Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life (2000) (110)
- Comparison of pergolide and bromocriptine therapy in parkinsonism (1983) (108)
- Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients (2004) (104)
- Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience (1998) (100)
- Metabolomic biomarkers as strong correlates of Parkinson disease progression (2017) (94)
- GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up (2016) (93)
- Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets (2016) (92)
- Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
- Levodopa therapy for Parkinson disease (2016) (88)
- Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. (1994) (86)
- Markers of dopamine metabolism in Parkinson's disease (1992) (82)
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) (2012) (82)
- Blink rates in parkinsonism (1982) (79)
- PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASE (1981) (79)
- A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's disease (2016) (78)
- Effect of Aging on Tyrosine Hydroxylase Protein Content and the Relative Number of Dopamine Nerve Terminals in Human Caudate (1991) (76)
- Motor function in the normal aging population: treatment with levodopa. (1985) (75)
- CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites (1989) (72)
- Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection (1997) (72)
- Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. (2017) (66)
- Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease (2009) (65)
- Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial (2019) (64)
- Episodic hyperhidrosis, hypothermia, and agenesis of corpus callosum (1983) (64)
- Buspirone, Parkinson's disease, and the locus ceruleus. (1986) (62)
- Protection against Parkinson’s disease progression: Clinical experience (2008) (61)
- Effects of Enhanced Striatal Dopamine Turnover In Vivo on Glutathione Oxidation (1994) (60)
- Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study (2001) (59)
- Dystonia in untreated parkinsonism. (1986) (59)
- Overnight Switch From Oral Dopaminergic Agonists to Transdermal Rotigotine Patch in Subjects With Parkinson Disease (2007) (59)
- Subcutaneously administered apomorphine (2004) (58)
- Lisuride versus bromocriptine treatment in Parkinson disease (1982) (56)
- CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease (2011) (56)
- Neuropsychological performance in lateralized parkinsonism. (1988) (54)
- Hyperhidrosis and hypothermia responsive to oxybutynin (1988) (54)
- Clinical trials of neuroprotection for Parkinson’s disease (2004) (54)
- The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease (2001) (53)
- Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease (2014) (53)
- Visual and mechanical control of postural and kinetic tremor in cerebellar system disorders. (1988) (53)
- Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER (2012) (52)
- Tetrahydrobiopterin in dystonia (1986) (51)
- The neurotoxicity of the rat poison vacor. A clinical study of 12 cases. (1980) (50)
- Pharmacokinetic‐pharmacodynamic crossover comparison of two levodopa extension strategies (2009) (50)
- Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. (1989) (48)
- Micrographia as a focal sign of neurological disease. (1983) (47)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- New developments in levodopa therapy (2004) (47)
- Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm (2013) (47)
- Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type (1992) (46)
- Standardized training tools for the UPDRS activities of daily living scale: Newly available teaching program (2003) (46)
- Levodopa therapy for Parkinson disease: A look backward and forward (2020) (46)
- Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease (2012) (43)
- Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease (2022) (42)
- Effective Delivery of Apomorphine in the Management of Parkinson Disease: Practical Considerations for Clinicians and Parkinson Nurses (2015) (42)
- Intraoperative MRI for deep brain stimulation lead placement in Parkinson’s disease: 1 year motor and neuropsychological outcomes (2016) (42)
- Treatment of dystonia with tetrahydrobiopterin. (1983) (42)
- The Pharmacology of Levodopa in Treatment of Parkinson’s Disease: An Update (1989) (40)
- Comparison of the Fahn‐Tolosa‐Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale (2018) (37)
- Neoplastic angioendotheliosis (1983) (36)
- Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson Disease (2009) (36)
- In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys—and in Lewy body-containing human brain specimens (2003) (36)
- Apomorphine therapy in Parkinson's disease: a review (2007) (35)
- Peripheral beta‐adrenergic blockade treatment of parkinsonian tremor (1984) (35)
- A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. (1994) (35)
- Elevated levels of histamine metabolites in cerebrospinal fluid of aging, healthy humans. (1988) (35)
- Persistent movement disorders induced by buspirone (1993) (35)
- Norepinephrine: the next therapeutics frontier for Parkinson's disease (2012) (35)
- Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine (1990) (34)
- Islet-cell surface antibodies in a patient with diabetes mellitus after rodenticide ingestion. (1978) (34)
- CSF dopamine‐‐hydroxylase activity in Parkinson's disease (1985) (34)
- Actively Transported Levodopa Prodrug XP21279: A Study in Patients With Parkinson Disease Who Experience Motor Fluctuations (2012) (34)
- Subcutaneously administered apomorphine: Pharmacokinetics and metabolism (2004) (32)
- Unloading and shortening reactions in Parkinson's disease. (1978) (30)
- Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson’s Disease-Associated LRRK2 Gene Mutations (2017) (30)
- Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. (2013) (30)
- New levodopa therapeutic strategies. (2016) (30)
- Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. (2001) (29)
- Hiccup with dexamethasone therapy (1982) (29)
- Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. (1990) (28)
- Cerebrospinal Fluid C3a Increases with Age, But Does Not Increase Further in Alzheimer’s Disease (1997) (28)
- Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
- Speech therapy in Parkinson's disease (2002) (28)
- Unmet needs in Parkinson disease: Motor and non-motor. (2020) (28)
- Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease (2017) (27)
- Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease (1998) (27)
- Recent advances in CSF biomarkers for Parkinson's disease. (2012) (26)
- The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol (1997) (26)
- Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease. (2019) (26)
- Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls (2019) (26)
- Clinical studies with and pharmacokinetic considerations of sustained‐release levodopa (1992) (26)
- Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism. (1984) (26)
- Ceruloplasmin immunoreactivity in neurodegenerative disorders (2001) (26)
- Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. (1989) (25)
- Levodopa therapeutics for Parkinson's disease: new developments. (2009) (25)
- Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry (2017) (24)
- The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. (2020) (24)
- Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor (2020) (23)
- TRH AND SPINOCEREBELLAR DEGENERATION (1982) (23)
- ‘On—off’ effects: the new challenge in parkinsonism (1983) (22)
- Cholecystokinin and neurotensin gradients in human CSF. (1985) (22)
- Tardive Dyskinesia Caused by Tetrabenazine (2013) (22)
- Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
- Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's disease (2019) (21)
- Altered Guanosine and Guanine Concentrations in Rabbit Striatum Following Increased Dopamine Turnover (1998) (21)
- Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease. (2019) (20)
- Treatment strategies for extension of levodopa effect. (1992) (20)
- Characterization of dopamine-depleting activity of Nocardia asteroides strain GUH-2 culture filtrate on PC12 cells. (2004) (20)
- MAO-B inhibitor know-how (2009) (20)
- Parkinson's Disease: The Treatment Options (1999) (19)
- Electroencephalographic findings in unmedicated, neurologically and intellectually intact Tourette syndrome patients. (1986) (19)
- Penicillamine as a controversial treatment for Wilson's disease (1999) (19)
- Amantadine and other antiglutamate agents (2002) (19)
- Neuroprotection by anti-oxidant strategies in Parkinson's disease. (1993) (18)
- Early complement activation increases in the brain in some aged normal subjects (2004) (18)
- A comparison of two iatrogenic dyskinesias. (1983) (18)
- Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson’s Disease Psychosis (2018) (17)
- Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. (1994) (17)
- Severity of Parkinson's disease and the dosage of bromocriptine (1984) (17)
- Levodopa therapeutics: New treatment strategies (1993) (17)
- Monoamine Changes in the Brain of BALB/c Mice Following Sub-Lethal Infection with Nocardia asteroides (GUH-2) (2000) (17)
- Dystonia and hypokinesis with putaminal necrosis after methanol intoxication. (1988) (17)
- Treatment of depression in idiopathic Parkinson's disease (2002) (17)
- Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid (1995) (16)
- Nocardia asteroides Culture Filtrates Cause Dopamine Depletion and Cytotoxicity in PC12 Cells (2003) (16)
- CSF GABA in caregiver spouses of Alzheimer patients. (1989) (16)
- Sensory Evoked Responses in Tourette Syndrome (1988) (15)
- Tiaspirone in schizophrenia. (1987) (15)
- Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations (2017) (15)
- Drugs to treat dementia and psychosis (2002) (14)
- New Drugs for the Treatment of Parkinson's Disease (2000) (14)
- Therapeutics of Tourette syndrome. New medication approaches. (1992) (14)
- Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress (2016) (14)
- Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation (1998) (14)
- MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
- CSF Nrf2 and HSPA8 in Parkinson’s disease patients with and without LRRK2 gene mutations (2016) (13)
- Quantitative Analysis of Voice in Parkinson Disease Compared to Motor Performance: A Pilot Study. (2015) (13)
- Dose-Response Effects of Chronic Methylphenidate Administration on Late Event-Related Potentials in Attention Deficit Disorder (1988) (12)
- Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials (2021) (12)
- Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study (2021) (12)
- Dystonia: treatment with bromocriptine. (1985) (11)
- Neuroprotection for Parkinson's disease. (2006) (11)
- Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. (1993) (11)
- A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. (2020) (11)
- Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effects. (1994) (11)
- Immunocytochemical Detection of Anti-Hippocampal Antibodies in Alzheimer's Disease and Normal Cerebrospinal Fluid (1997) (11)
- An Update on CSF Biomarkers of Parkinson’s Disease (2013) (10)
- Erratum: Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid (Arch. Gerontol. Geriatr., 11 (1990) 85-95) (1991) (10)
- The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. (1997) (10)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- “Sensory trick” in hemichorea‐hemiballism and in Parkinson's disease tremor (2010) (9)
- Lack of evidence for Nocardia asteroides in brain specimens from Lewy body-containing disorders. (2005) (9)
- Reduction of dyskinesias and psychiatric disability with clozapine over different time courses (1992) (9)
- Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. (1983) (9)
- Measurement of Acute Phase Proteins in the Rat Brain: Contribution of Vascular Contents (1999) (9)
- Long-term follow-up of a randomized AAV 2-GAD gene therapy trial for Parkinson ’ s disease (2017) (9)
- Influence of Repeated Levodopa Administration on Rabbit Striatal Serotonin Metabolism, and Comparison Between Striatal and CSF Alterations (1998) (9)
- Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells (2000) (9)
- CSF dopamine-beta-hydroxylase activity in Parkinson's disease. (1985) (9)
- What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations? (2019) (9)
- SCA 17 phenotype with intermediate triplet repeat number (2014) (8)
- Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
- Parkinson’s Disease: Etiologic Considerations (2000) (8)
- Transient ophthalmoparesis with doxepin overdosage (1981) (8)
- Caloric vestibular stimulation for the management of motor and non-motor symptoms in parkinson's disease: Intention-to-treat data (2019) (8)
- On demand therapy for Parkinson’s disease patients: Opportunities and choices (2021) (8)
- The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography (2017) (8)
- Milacemide: Safety assessment in senile dementia of the Alzheimer type (1992) (7)
- Peripheral neuropathy following amitriptyline overdose. (1985) (7)
- Ineffective treatment of essential tremor with an alcohol, methylpentynol. (1986) (7)
- Comparison of PCR and culture for detection of Nocardia asteroides in brain specimens from experimentally infected BALB/c mice. (2004) (7)
- Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study (2018) (7)
- Is levodopa toxic? (2011) (7)
- Comparison of methods for analysis of CSF proteins in patients with Alzheimer's disease. (1987) (6)
- Pimavanserin use in a movement disorders clinic: a single-center experience (2018) (6)
- The Story of Istradefylline—The First Approved A2A Antagonist for the Treatment of Parkinson’s Disease (2015) (6)
- DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
- Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study. (1990) (6)
- Nocardia asteroides‐Induced movement abnormalities in mice: Relevance for Parkinson's disease? (2016) (6)
- Psychosocial counseling in Parkinson's disease (2002) (6)
- Peripheral carbidopa affects striatal monoamine oxidase activity (1985) (6)
- DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
- Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
- Successful Management of Hemorrhage-Associated Hemiballism After Subthalamic Nucleus Deep Brain Stimulation with Pallidal Stimulation: a Case Report. (2015) (6)
- Localizing imbalance in progressive supranuclear palsy (2011) (5)
- Neuropharmacological Intervention with Motor System Aging (1988) (5)
- Predicting the development of levodopa-induced dyskinesias (2014) (5)
- Dopaminergic Agonists in Parkinson’s Disease (2010) (5)
- Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis (2018) (5)
- Application of Neuromelanin MR Imaging in Parkinson Disease (2022) (5)
- Physical and occupational therapy in Parkinson's disease (2002) (5)
- A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s disease (2021) (5)
- Increased CSF HVA response to arecoline challenge in Alzheimer's disease (2005) (5)
- The pharmacodynamics of placebo (2015) (5)
- DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
- Subcutaneous Administration of Carbidopa Enhances Oral Levodopa Pharmacokinetics: A Series of Studies Conducted in Pigs, Mice, and Healthy Volunteers. (2019) (4)
- Wilson's Disease (2010) (4)
- Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers. (1993) (4)
- Levodopa Administration to Normal Rats: Influence on Striatal Oxidized Glutathione Concentration a (1994) (4)
- Pterin abnormalities in dystonia: a metabolic marker with therapeutic implications. (1988) (4)
- A unique protein in normal human cerebrospinal fluid. (1983) (4)
- Pharmacokinetics of Opicapone and Effect on Comt and Levodopa Pharmacokinetics in Patients with Parkinson's Disease (2019) (4)
- Delayed Hypersensitivity Reaction to OnabotulinumtoxinA (2018) (4)
- A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. (2007) (4)
- Monoamine neurotransmitter metabolites and hydroxylase Cofactor in alzheimer-type dementia and normals (1986) (3)
- Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
- Inter-Rater Reliability of the Essential Tremor Rating Assessment Scale (TETRAS) (S32.004) (2012) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. (1991) (3)
- The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program (2022) (3)
- Relief of parkinsonism and dyskinesia (2010) (3)
- At last, a randomised controlled trial of apomorphine infusion (2018) (3)
- Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. (1991) (3)
- Non-specific binding of normal human IgG, including F(ab′)2 and Fc fragments, to embryonic rat brain neurons and human cortex synaptosomes (1992) (3)
- DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
- The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis (2016) (3)
- Treatment of resting tremor by beta-adrenergic blockade. (1984) (3)
- Orthostatic tremor: the phenomenon of 'paradoxical clonus'. (1990) (3)
- Chorea: Causes and management (2014) (2)
- Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations (2021) (2)
- Abnormal apocrine secretory cell mitochondria in a Huntington disease patient (2012) (2)
- Micrographia after thalamo-mesencephalic infarction. (1999) (2)
- Medication-Induced Movement Disorders: Medication-induced tremors (2015) (2)
- Electrophoresis and immunoblot of cerebrospinal fluid proteins in spasmodic torticollis (1986) (2)
- Beta blockade of parkinsonian tremor (1983) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Micrographia after thalamo-mesencephalic infarction [2] (multiple letters) (1999) (2)
- Neuroprotective Effects of MAO-B Inhibition: Clinical Studies in Parkinson’s Disease (1993) (2)
- New delivery systems for antiparkinsonian drugs. (1999) (2)
- Clinical, Pharmacokinetic, and Pharmacodynamic Effects of Tolcapone Withdrawal in Levodopa-Treated Patients with Parkinsonism (2000) (2)
- Post‐traumatic Origin of Unilateral Restless Leg Syndrome (2018) (1)
- Neurosarcoidosis and headache. (1984) (1)
- Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study (P5.372) (2016) (1)
- Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies (S4.003) (2019) (1)
- New Perspectives in the Treatment of Parkinson's Disease (1986) (1)
- Rotigotine: a viewpoint by Peter LeWitt. (2005) (1)
- Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation (2017) (1)
- Serotonin Transporter 5HTTLPR Polymorphism and Neurocognitive Outcomes in Lithium-Treated Pediatric and Adolescent Bipolar Disorder (2013) (1)
- DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
- EMD 23,448: Effects of a putative dopamine autoreceptor agonist in chorea (2005) (1)
- Tobacco Smoking, Nicotine, and Neuroprotection (2002) (1)
- Safety and Efficacy of Continuous Apomorphine Infusion in Patients with Parkinson's disease: Results from a Phase 3, Open-label Study (2020) (1)
- DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
- Double-Blind Study of an Actively-Transported Levodopa Prodrug, XP21279, in Parkinson Disease (P02.075) (2013) (1)
- Self-Perception of Voice and Swallowing Handicap in Parkinson's Disease. (2021) (1)
- Response to "Neuromelanin? MRI of Noradrenergic and Dopaminergic Neurons". (2022) (1)
- Ceruoplasmin Is Increased in Cerebrospinal Fluid in Alzheimer's Disease but Not Parkinson's Disease (1994) (1)
- The Challenge of Managing Mild Parkinson's Disease (2000) (1)
- Motor function in the norimal aging population (1985) (1)
- Improving Responses to Levodopa (2003) (1)
- ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical & Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cervical Dystonia: Baseline Data and Interim Outcomes Data (P01.228) (2012) (1)
- “Paradoxical clonus”: Rhythmic contractions evoked in passively shortened muscle (1978) (1)
- DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
- Portrayal of progressive supranuclear palsy in the 16th century (2017) (1)
- MUSCARINIC SUPERSENSITIVITY IN ALZHEIMER'S DISEASE–POS.S I BLE DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS (1988) (1)
- Test-Retest Reliability of a Parkinson's Disease Monitoring System (S03.003) (2013) (1)
- Rotigotine (2016) (0)
- New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
- The class of 1975: a differential diagnosis. (1975) (0)
- Contributors (1987) (0)
- A clinician’s approach to chorea (2014) (0)
- Improving Levodopa Delivery: IPX203, a Novel Extended-Release Carbidopa-Levodopa Formulation (2023) (0)
- Comment on ‘Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson's Disease’ by Hiller et al (2018) (0)
- Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease. (2023) (0)
- P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring (2009) (0)
- DA agonists ‐ Overview (2002) (0)
- Letters to the editor (1985) (0)
- Pharmacokinetic and safety characterisation of carbidopa/levodopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson's disease (2018) (0)
- Diagnostic metabolomic profiling of Parkinson's disease biospecimens (2022) (0)
- Contributors (1981) (0)
- P2.147 Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients (2009) (0)
- Neurobehavioral toxicology (1980) (0)
- Pharmacokinetic and Pharmacodynamic Studies with Controlled-Release Carbidopa/Levodopa (1990) (0)
- Cerebrospinal fluid biomarkers of Parkinson's disease: an update (2020) (0)
- Role of Hydroxylase Cofactor in Regulating Dopamine Synthesis: Relevance to Neurological Disorders (1986) (0)
- Patients Reported Improvement in Quality of “OFF” time, Severity of Non-Motor Fluctuations, and Medication Satisfaction in the OPTI-ON Study (S32.007) (2023) (0)
- A Pooled Analysis for Eight Randomized Controlled Trials of Istradefylline, an Adenosine A2A Receptor Antagonist: Efficacy as Adjunct to Levodopa in Parkinson’s Disease (PD) (P3.8-030) (2019) (0)
- **Poster 91 ANCHOR‐CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cervical Dystonia: Baseline Data and Cycle One Outcomes Data (2012) (0)
- Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease. (2020) (0)
- Biological markers in Alzheimer's and Parkinson's disease (1986) (0)
- DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
- A New Editor-in Chief for Clinical Neuropharmacology (2004) (0)
- Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis (2022) (0)
- 1st Sandoz Symposium on the Treatment of Parkinson’s Disease, Vol. 33(suppl 1), 1993 (1993) (0)
- A multiparametric MEG study of the effect of medications on neuronal oscillations in generalized or cervical dystonia (2017) (0)
- 1.12.2 ADVANCES IN CSF BIOMARKERS OF PARKINSON'S DISEASE (2012) (0)
- Body Fluid and Tissue Analysis (2007) (0)
- Norepinephrine: the next therapeutics frontier for Parkinson's disease (2012) (0)
- Inhaled Levodopa (CVT-301) for Treatment of off Periods in Parkinson's Disease: Efficacy as Assessed by 39-Item Parkinson's Disease Quality of Life (QoL) Questionnaire (2019) (0)
- Author/Subject Indexes (1993) (0)
- Chapter 10 COVID-19 Infection: Impaired Olfaction, Movement Disorders, Encephalopathy, and Neuropsychiatric Manifestations (2021) (0)
- Introduction. (2020) (0)
- 2.247 Safe and tolerable switching from oral dopaminergic agonists to transdermal rotigotine in Parkinson's disease (2007) (0)
- 2.244 Efficacy of rotigotine transdermal patch as adjunct to levodopa in subgroups of advanced-stage Parkinson's patients (2007) (0)
- Expensive placebo better than cheap placebo in PD trial (2015) (0)
- Clinical Neuropharmacology: Editor's note (2005) (0)
- cold?greater resistance to the common Do parkinsonian patients have a (0)
- Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa (2023) (0)
- Patients’ Experience of Parkinson’s Disease Following Treatment with Inhaled Levodopa: Results from a Phase 2b Study (P5.351) (2016) (0)
- New options for treatment of Parkinson's disease. (1997) (0)
- Neurodegenerative Diseases: Neurological aspects of Wilson's disease (2005) (0)
- Brainstem Modulation Therapy for the Management of Parkinson's Disease: Results from a Single-Site Randomized Controlled Trial (2019) (0)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- Continuous Subcutaneous Administration of Carbidopa Enhances Levodopa Pharmacokinetics: A Series of Studies Conducted in the Pig, Mouse and Healthy Volunteers (S40.002) (2016) (0)
- The Clinical Development of Levodopa Inhalation Powder (2023) (0)
- Continuous, Subcutaneous Apomorphine Infusion for Persistent Motor Fluctuations in Parkinson’s Disease: Full results of the AP2-3000 open-label study (S32.008) (2023) (0)
- A pilot magnetoencephalographic study of coherence in cervical dystonia and meige syndrome (2017) (0)
- Acknowledgment of Reviewers (2016) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Peter A. Lewitt?
Peter A. Lewitt is affiliated with the following schools:
